SUMMARY OF CHANGES:

INSTRUMENT NOS. 99 to 104 of 2021

Statements of Principles Nos. 99 to 104 of 2021 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 1 October 2021. The day of commencement as specified in each of these Instruments is 1 November 2021.

These Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the Legislation Act 2003 (Legislation Act). In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from http://www.legislation.gov.au.

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the Veterans' Entitlements Act 1986 (the VEA), on the Authority's website at http://www.rma.gov.au.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is also available on the Authority's website at http://www.rma.gov.au.

For further information contact:

The Registrar
Repatriation Medical Authority
GPO Box 1014
Brisbane  Qld  4001

T  +61 7 3815 9404
F  +61 7 3815 9412
E  info@rma.gov.au

13 October 2021
## SUMMARY OF CHANGES

<table>
<thead>
<tr>
<th>Instr. No.</th>
<th>Title</th>
<th>Date of Commencement</th>
<th>ICD-10-AM Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>REPEALS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>99 &amp; 100/2021</td>
<td>dental pulp and periapical disease</td>
<td>1/11/2021</td>
<td>K04</td>
</tr>
<tr>
<td>101 &amp; 102/2021</td>
<td>chronic gastritis and chronic gastropathy</td>
<td>1/11/2021</td>
<td>Nil</td>
</tr>
<tr>
<td>Instrument No.</td>
<td>Condition</td>
<td>Changes</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 99 & 100/2021 | Dental pulp and periapical disease | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 9 March 2021 concerning dental pulp and apical disease in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For RH SoP (Instrument No. 99/2021)  
• adopting the latest revised Instrument format, which commenced in 2015;  
• specifying a day of commencement for the Instrument in section 2;  
• revising the name of the condition from 'dental pulp and apical disease' to 'dental pulp and periapical disease';  
• new definition of 'dental pulp and periapical disease' in subsection 7(2);  
• revising ICD-10-AM codes for 'dental pulp and periapical disease' in subsection 7(3);  
• revising the reference to 'ICD-10-AM code' in subsection 7(4);  
• revising the factors in subsections 9(1) and 9(10) concerning having dental caries;  
• revising the factors in subsections 9(2) and 9(11) concerning having periodontitis involving the periodontium;  
• revising the factors in subsections 9(3) and 9(12) concerning having trauma;  
• revising the factors in subsections 9(4) and 9(13) concerning undergoing surgery;  
• revising the factors in subsections 9(5) and 9(14) concerning undergoing a non-invasive dental or orthodontic procedure;  
• revising the factors in subsections 9(6) and 9(15) concerning having smoked tobacco products;  
• new factors in subsections 9(8) and 9(17) concerning having scleroderma or Sjögren syndrome;  
• new factors in subsections 9(9) and 9(18) concerning having osteonecrosis of the jaw;  
• deleting the factors concerning having blunt injury to the supporting structures of the affected tooth, as these are now covered by the factors in subsections 9(3) and 9(12) concerning having trauma;  
• new definitions of 'dental concussion', 'luxation', 'MRCA', 'one pack-year', 'periapical abscess', 'periapical cyst', 'periapical periodontitis', 'pulpitis', 'surgery', 'trauma involving the affected tooth' and 'VEA' in Schedule 1 - Dictionary;  
• revising the definitions of 'non-invasive dental or orthodontic procedure' and 'relevant service' in Schedule 1 - Dictionary; and  
• deleting the definitions of 'apical abscess', 'apical cyst', 'apical periodontitis', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'trauma to the region of the affected tooth'. For BoP SoP (Instrument No. 100/2021)  
• adopting the latest revised Instrument format, which commenced in 2015;  
• specifying a day of commencement for the Instrument in section 2;  
• revising the name of the condition from 'dental pulp and apical disease' to 'dental pulp and periapical disease';  
• new definition of 'dental pulp and periapical disease' in subsection 7(2);  
• revising ICD-10-AM codes for 'dental pulp and periapical disease' in subsection 7(3);  
• revising the reference to 'ICD-10-AM code' in subsection 7(4);  
• revising the factors in subsections 9(1) and 9(7) concerning having dental caries;  
• revising the factors in subsections 9(2) and 9(8) concerning having periodontitis involving the periodontium;  
• revising the factors in subsections 9(3) and 9(9) concerning having trauma;  
• revising the factors in subsections 9(4) and 9(10) concerning undergoing surgery;  
• revising the factors in subsections 9(5) and 9(11) concerning undergoing a non-invasive dental or orthodontic procedure, by the inclusion of a note;  
• revising the factors in subsections 9(6) and 9(12) concerning having smoked tobacco products;  
• deleting the factors concerning having blunt injury to the supporting structures of the affected tooth, as these are now covered by the factors in subsections 9(3) and 9(9) concerning having trauma; |
### SUMMARY OF CHANGES

- new definitions of 'dental concussion', 'luxation', 'MRCA', 'one pack-year', 'periapical abscess', 'periapical cyst', 'periapical periodontitis', 'pulpitis' 'surgery', 'trauma involving the affected tooth' and 'VEA' in Schedule 1 - Dictionary;
- revising the definitions of 'non-invasive dental or orthodontic procedure' and 'relevant service' in Schedule 1 - Dictionary; and
- deleting the definitions of 'apical abscess', 'apical cyst', 'apical periodontitis', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'trauma to the region of the affected tooth'.

The determination of these Instruments finalises the investigation in relation to **dental pulp and apical disease** as advertised in the Government Notices Gazette of 9 March 2021.

<table>
<thead>
<tr>
<th>Instruments</th>
<th>Condition</th>
<th>Description</th>
</tr>
</thead>
</table>
| 101 & 102/2021 | chronic gastritis and chronic gastropathy | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning **chronic gastritis and chronic gastropathy** in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered. The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include: For **RH SoP (Instrument No. 101/2021)**

- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definitions of 'chronic gastritis' and 'chronic gastropathy' in subsection 7(2);
- revising the factors in paragraphs 9(1)(a) and 9(9)(a) concerning having a *Helicobacter pylori* infection of the gastric mucosa, for chronic gastritis only;
- revising the factors in paragraphs 9(1)(b) and 9(9)(b) concerning having *Helicobacter heilmannii sensu lato* infection of the gastric mucosa, for chronic gastritis only;
- revising the factors in paragraphs 9(1)(c) and 9(9)(c) concerning having an infection of the gastric mucosa from the specified list of infections, for chronic gastritis only;
- revising the factors in paragraphs 9(1)(d) and 9(9)(d) concerning being in an immunocompromised state as specified, for chronic gastritis only;
- revising the factors in paragraphs 9(1)(e) and 9(9)(e) concerning taking an immune checkpoint inhibitor, for chronic gastritis only;
- revising the factor in paragraph 9(2)(a) concerning having reflux of bile acids into the stomach, for clinical onset of chronic gastropathy only;
- revising the factor in paragraph 9(2)(b) concerning taking a non-topical, non-steroidal, anti-inflammatory drug, including aspirin, for clinical onset of chronic gastropathy only;
- revising the factor in paragraph 9(2)(c) concerning taking a drug from the Specified List 1 of drugs, for clinical onset of chronic gastropathy only;
- revising the factor in paragraph 9(2)(d) concerning consuming alcohol, for clinical onset of chronic gastropathy only;
- revising the factor in paragraph 9(2)(e) concerning undergoing a course of therapeutic radiation for cancer, for clinical onset of chronic gastropathy only;
- revising the factor in paragraph 9(2)(f) concerning having received yttrium-90 microspheres, for clinical onset of chronic gastropathy only;
- revising the factor in subsection 9(3) concerning having reflux of bile acids into the stomach, for clinical worsening;
- revising the factor in subsection 9(4) concerning taking a non-topical, non-steroidal, anti-inflammatory drug, including aspirin, for clinical worsening;
- revising the factor in subsection 9(5) concerning taking a drug from the Specified List 2 of drugs, for clinical worsening;
- revising the factor in subsection 9(6) concerning consuming alcohol, for clinical worsening;
- revising the factor in subsection 9(7) concerning undergoing a course of therapeutic radiation for cancer, for clinical worsening;
- revising the factor in subsection 9(8) concerning having received yttrium-90 microspheres, for clinical worsening;
- deleting the factors concerning having received a cumulative equivalent dose of ionising radiation as these are covered by the factors in paragraph 9(2)(e) and subsection 9(7) concerning undergoing a course of therapeutic radiation for cancer;
- new definitions of 'chronic renal failure', *Helicobacter heilmannii sensu lato*, 'immunosuppressive drug', 'MRCA', 'Specified List 1 of drugs', 'Specified List 2 of drugs', 'specified list of infections' and 'VEA' in Schedule 1 - Dictionary; |
• revising the definitions of 'immunocompromised state as specified' and 'relevant service' in Schedule 1 - Dictionary; and
• deleting the definitions of 'a drug or a drug from a class of drugs from Specified List 1', 'a drug or a drug from a class of drugs from Specified List 2', 'a specified infection', 'alcohol' and 'cumulative equivalent dose'.

For BoP SoP (Instrument No. 102/2021)
• adopting the latest revised Instrument format, which commenced in 2015;
• specifying a day of commencement for the Instrument in section 2;
• revising the definitions of 'chronic gastritis' and 'chronic gastropathy' in subsection 7(2);
• revising the factors in paragraphs 9(1)(a) and 9(9)(a) concerning having a Helicobacter pylori infection of the gastric mucosa, for chronic gastritis only;
• revising the factors in paragraphs 9(1)(b) and 9(9)(b) concerning having Helicobacter heilmannii sensu lato infection of the gastric mucosa, for chronic gastritis only;
• revising the factors in paragraphs 9(1)(c) and 9(9)(c) concerning having an infection of the gastric mucosa from the specified list of infections, for chronic gastritis only;
• revising the factors in paragraphs 9(1)(d) and 9(9)(d) concerning being in an immunocompromised state as specified, for chronic gastritis only;
• revising the factors in paragraphs 9(1)(e) and 9(9)(e) concerning taking an immune checkpoint inhibitor, for chronic gastritis only;
• revising the factor in paragraph 9(2)(a) concerning having reflux of bile acids into the stomach, for clinical onset of chronic gastropathy only;
• revising the factor in paragraph 9(2)(b) concerning taking a non-topical, non-steroidal, anti-inflammatory drug, including aspirin, for clinical onset of chronic gastropathy only;
• revising the factor in paragraph 9(2)(c) concerning taking a drug from the Specified List 1 of drugs, for clinical onset of chronic gastropathy only;
• revising the factor in paragraph 9(2)(d) concerning consuming an average of at least 350 grams of alcohol, for clinical onset of chronic gastropathy only;
• revising the factor in paragraph 9(2)(e) concerning undergoing a course of therapeutic radiation for cancer, for clinical onset of chronic gastropathy only;
• revising the factor in paragraph 9(2)(f) concerning having received yttrium-90 microspheres, for clinical onset of chronic gastropathy only;
• revising the factor in subsection 9(3) concerning having reflux of bile acids into the stomach, for clinical worsening;
• revising the factor in subsection 9(4) concerning taking a non-topical, non-steroidal, anti-inflammatory drug, including aspirin, for clinical worsening;
• revising the factor in subsection 9(5) concerning taking a drug from the Specified List 2 of drugs, for clinical worsening;
• revising the factor in subsection 9(6) concerning consuming alcohol, for clinical worsening;
• revising the factor in subsection 9(7) concerning undergoing a course of therapeutic radiation for cancer, for clinical worsening;
• revising the factor in subsection 9(8) concerning having received yttrium-90 microspheres, for clinical worsening;
• deleting the factors concerning having received a cumulative equivalent dose of ionising radiation, as these are covered by the factors in paragraph 9(2)(e) and subsection 9(7) concerning undergoing a course of therapeutic radiation for cancer;
• new definitions of 'chronic renal failure', 'Helicobacter heilmannii sensu lato', 'immunosuppressive drug', 'MRCA', 'Specified List 1 of drugs', 'Specified List 2 of drugs', 'specified list of infections' and 'VEA' in Schedule 1 - Dictionary;
• revising the definitions of 'immunocompromised state as specified' and 'relevant service' in Schedule 1 - Dictionary; and
• deleting the definitions of 'a drug or a drug from a class of drugs from Specified List 1', 'a drug or a drug from a class of drugs from Specified List 2', 'a specified infection', 'alcohol' and 'cumulative equivalent dose'.

The determining of these Instruments finalises the investigation in relation to chronic gastritis and chronic gastropathy as advertised in the Government Notices Gazette of 5 January 2021.
SUMMARY OF CHANGES

The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:

For RH SoP (Instrument No. 103/2021)
- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'malignant neoplasm of the pancreas' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factor in subsection 9(1) concerning having smoked tobacco products, for clinical onset only;
- revising the factor in subsection 9(2) concerning the oral use of smokeless tobacco, for clinical onset only;
- revising the factor in subsection 9(3) concerning being overweight or obese, for clinical onset only;
- new factor in subsection 9(6) concerning having acute pancreatitis, for clinical onset only;
- revising the factor in subsection 9(7) concerning inhaling, ingesting or having cutaneous contact with DDT, for clinical onset only;
- revising the factor in subsection 9(9) concerning having received ionising radiation to the pancreas, from internal deposition of a therapeutic or diagnostic substance which emits alpha particles, for clinical onset only;
- new factor in subsection 9(11) concerning having infection with hepatitis B virus, for clinical onset only;
- new factor in subsection 9(12) concerning having infection with hepatitis C virus, for clinical onset only;
- new definitions of 'being overweight or obese', 'BMI', 'MRCA', 'one pack-year' and 'VEA' in Schedule 1 - Dictionary;
- revising the definition of 'inhaling, ingesting or having cutaneous contact with DDT' and 'relevant service' in Schedule 1 - Dictionary; and
- deleting the definitions of 'being obese' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.

For BoP SoP (Instrument No. 104/2021)
- adopting the latest revised Instrument format, which commenced in 2015;
- specifying a day of commencement for the Instrument in section 2;
- revising the definition of 'malignant neoplasm of the pancreas' in subsection 7(2);
- revising the reference to 'ICD-10-AM code' in subsection 7(4);
- revising the factor in subsection 9(1) concerning having smoked tobacco products, for clinical onset only;
- revising the factor in subsection 9(2) concerning the oral use of smokeless tobacco, for clinical onset only;
- revising the factor in subsection 9(3) concerning being overweight or obese, for clinical onset only;
- new definitions of 'being overweight or obese', 'BMI', 'MRCA', 'one pack-year' and 'VEA' in Schedule 1 - Dictionary;
- revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
- deleting the definitions of 'being obese' and 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.

The determining of these Instruments finalises the investigation in relation to malignant neoplasm of the pancreas as advertised in the Government Notices Gazette of 9 March 2021.